Literature DB >> 30102999

Pathophysiology of levodopa-induced dyskinesia: Insights from multimodal imaging and immunohistochemistry in non-human primates.

Maude Beaudoin-Gobert1, Elise Météreau1, Sandra Duperrier1, Stéphane Thobois2, Léon Tremblay1, Véronique Sgambato3.   

Abstract

BACKGROUND: Dopaminergic and serotonergic degenerations alter pharmacological neurotransmission and structural markers in Parkinson's disease (PD). Alteration of diffusion measures in key brain regions depict MPTP/MDMA lesions in the monkey model of PD. Whether dopatherapy impacts such diffusion measures remains an open question.
OBJECTIVES: The aim of this study was to investigate the consequences of l-DOPA treatment on diffusion alterations, PET imaging and immunohistochemical markers in MPTP/MDMA-intoxicated monkeys.
METHODS: We acquired PET imaging and measures of mean diffusivity and fractional anisotropy longitudinally and correlated them with behavior and post-mortem fiber quantification.
RESULTS: Severity of l-DOPA-induced dyskinesia was correlated to serotonin transporter radioligand binding increases in the ventral striatum and the anterior cingulate cortex and decreases of mean diffusivity in the ventral striatum. After lesion of serotonergic fibers by MDMA and the second l-DOPA period, diffusion measures were no more altered while the serotonergic binding still increased in all regions of interest, despite abolition of dyskinesia. Interestingly, in the anterior cingulate cortex, the SERT radioligand binding was negatively correlated to the number of SERT fibers.
CONCLUSION: These results show that the increase of SERT radioligand binding is not systematically paralleled by an increase of SERT fibers and does not always reflect the presence of LID. More specifically, our study suggest that SERT increase may be underpinned by an increased density of serotonergic fibers after MPTP and the first l-DOPA period, and by an elevation of SERT itself after MDMA and the second l-DOPA period. This highlights that DTI is complementary to PET imaging to decipher pathophysiological mechanisms underlying l-DOPA-induced dyskinesia in a non-human primate model of PD.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal model; Diffusion tensor imaging; Dyskinesia; Neuroimaging; PET imaging; Parkinson's disease; Serotonin

Mesh:

Substances:

Year:  2018        PMID: 30102999     DOI: 10.1016/j.neuroimage.2018.08.016

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  4 in total

Review 1.  Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.

Authors:  Abdeslam Chagraoui; Giuseppe Di Giovanni; Philippe De Deurwaerdère
Journal:  Biomolecules       Date:  2022-02-01

2.  Increased Expression of Alpha-, Beta-, and Gamma-Synucleins in Brainstem Regions of a Non-Human Primate Model of Parkinson's Disease.

Authors:  Sandra Duperrier; Analia Bortolozzi; Véronique Sgambato
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

Review 3.  L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning.

Authors:  Abdeslam Chagraoui; Marie Boulain; Laurent Juvin; Youssef Anouar; Grégory Barrière; Philippe De Deurwaerdère
Journal:  Int J Mol Sci       Date:  2019-12-31       Impact factor: 5.923

4.  A novel giant non-cholinergic striatal interneuron restricted to the ventrolateral striatum coexpresses Kv3.3 potassium channel, parvalbumin, and the vesicular GABA transporter.

Authors:  Lydia Lebenheim; Sam A Booker; Christian Derst; Torsten Weiss; Franziska Wagner; Clemens Gruber; Imre Vida; Daniel S Zahm; Rüdiger W Veh
Journal:  Mol Psychiatry       Date:  2022-04       Impact factor: 13.437

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.